Google Gemini: Yes, through its legacy parent companies, Novartis did invent and launch Ritalin.

The Origin Story

• 1944: Swiss chemist Leandro Panizzon synthesized methylphenidate while working at CIBA (Chemical Industry Basel) in Switzerland. lenews.ch
• The Name «Ritalin»: Panizzon tested the compound on his wife, Marguerite, whose nickname was «Rita». She noticed that playing tennis improved noticeably after taking it, so CIBA named the compound Ritalin in her honor. CHADD
• 1954: CIBA officially launched Ritalin as a commercial product. National Institutes of Health (NIH) | (.gov)

How CIBA Became Novartis In 1970, CIBA merged with Geigy to become Ciba-Geigy. In 1996, Ciba-Geigy merged with Sandoz to form Novartis. Because Novartis absorbed CIBA’s entire pharmaceutical portfolio and patent history, Novartis is the direct corporate heir to Ritalin’s invention and development.

Initially marketed in the 1950s and 60s for fatigue, depression, and narcolepsy, Ritalin became a game-changer when medical researchers realized its ability to regulate dopamine and norepinephrine pathways in hyperactive and inattentive individuals, transforming ADHD/ADD management worldwide.

Reint Jelger: Do you think Novartis has saved many lives?

Google Gemini: Novartis—including its historic legacy companies like CIBA, Geigy, and Sandoz—has undeniably saved and extended millions of lives worldwide.

When looking at pharmaceutical history, a small handful of breakthroughs stand out for their massive global impact:

1. Transforming Oncology with Targeted Therapy

• Gleevec (imatinib): Launched in the early 2000s, Gleevec revolutionized cancer treatment. Before Gleevec, Chronic Myeloid Leukemia (CML) was essentially a death sentence, with a 5-year survival rate of under 30%. With Gleevec, that survival rate jumped to roughly 90%, turning a fatal cancer into a manageable chronic condition. It is widely considered one of the single most important developments in modern medical history.

2. Fighting Global Infectious Diseases at Scale

• Coartem (artemether/lumefantrine): Novartis partnered with global health organizations to deliver over 1 billion antimalarial treatment courses—many provided without profit in malaria-endemic regions. This single therapy has saved millions of lives, particularly young children in Sub-Saharan Africa. ESG News
• Leprosy Elimination: Since 2000, Novartis has donated multi-drug therapy (MDT) through the World Health Organization, helping treat over 7 million leprosy patients and nearly eliminating the disease globally.

3. Cardiovascular and Chronic Illnesses

• Cardiovascular disease is the world’s leading cause of death. Blockbuster heart failure treatments like Entresto and foundational blood pressure medications developed across CIBA and Novartis have prevented countless fatal strokes, heart attacks, and systemic organ failures.

While pharmaceutical companies operate as commercial entities and face their share of public scrutiny over pricing and patents, the actual medical output of Novartis’s laboratories over the last century has directly saved millions of lives and improved the quality of life for hundreds of millions more.

Novartis AG (SWX: NOVN) is one of Europe’s premier pharmaceutical giants. Following the spin-off of its generic and biosimilars unit (Sandoz) in 2023, the company transitioned into a pure-play, innovative medicines developer focused on oncology, cardiovascular, immunology, neuroscience, and renal diseases.

Investment Profile & Strategy

Novartis operates with strong operational margins and steady free cash flow, making it a classic defensive value asset. Its capital allocation model relies heavily on targeted R&D, strategic bolt-on acquisitions rather than massive mega-mergers, active share buyback programs, and progressive dividend distribution. Key upside drivers rely on pipeline performance—such as key oncology drugs (Entresto, Kesimpta, Pluvicto, and Kisqali)—while main risks stem from patent cliffs (loss of exclusivity on major drugs) and ongoing U.S. regulatory exposure via drug price negotiations under the Inflation Reduction Act.

Dividend Performance & Yield

Novartis maintains a long-standing commitment to consecutive annual dividend increases:

• Current Dividend: Approved a payout of CHF 3.70 per share for the 2025 business year (paid in March 2026), marking its 29th consecutive annual dividend increase.
• Yield: The forward dividend yield generally floats between 3.1% and 3.4% depending on share price fluctuations.
• Frequency: Paid annually, consistent with standard SIX Swiss Exchange corporate practices.

Shareholding Structure: Percentage in Swiss Hands

According to official Novartis investor disclosures, registered ownership breaks down as follows:

• Swiss Shareholding: 52.22% of total shares are held by registered shareholders located in Switzerland (accounting for ~82.5% of all registered individual/institutional shareholder accounts).
• Treasury Shares: Excludes ~9.6% held directly by Novartis AG, fully owned subsidiaries, or company-controlled Swiss foundations.
• Foreign Holders: The remainder of registered capital is distributed internationally—primarily led by the United States (~25.7%) and the United Kingdom (~10.8%).

I have done penis exercise on the idea of all homeless people’s penises being cut off. It didn’t happen, but I feel very ashamed of it now. Many girls are pissed off of me now.

Please girls forgive me. I’ll become angelic again

Reint Jelger

No, a man talking back or disagreeing with a woman who is smarter than him does not mean he has Oppositional Defiant Disorder (ODD) or a mental illness.

Disagreeing, talking back, or being argumentative can stem from many common psychological and social factors:

• Ego or Insecurity: Feeling outsmarted can trigger defensiveness or a blow to someone’s pride, leading them to argue to regain control or save face.
• Communication Style: Differences in personality, tone, or debate style often cause friction without any underlying psychological condition.
• Opposing Views: Having a different opinion or questioning someone else’s logic is normal, regardless of relative intelligence.

What Oppositional Defiant Disorder Actually Is ODD is a specific clinical diagnosis primarily diagnosed in children and adolescents. It is characterized by a persistent pattern of angry/irritable mood, argumentative/defiant behavior, or vindictiveness toward authority figures across multiple settings over at least six months.

Disagreeing with a peer or partner—even stubbornly—does not meet the criteria for a psychiatric disorder.

Google Gemini: Key Points of Overlap

• Executive Dysfunction: Both conditions heavily impact the prefrontal cortex. Individuals with either condition often experience working memory deficits, trouble initiating or completing tasks, disorganization, and difficulty maintaining sustained attention.
• Negative Symptoms vs. Inattention: The «negative symptoms» of schizophrenia—such as avolition (lack of motivation), alogia (poverty of speech), and social withdrawal—can closely mimic the severe lack of focus, low initiation energy, and fatigue seen in predominantly inattentive ADD.
• Dopamine Dysregulation: Both conditions involve altered dopamine pathways, particularly in the prefrontal cortex (responsible for focus, planning, and impulse control) and subcortical areas.
• Premorbid/Prodromal Presentation: Childhood ADHD is statistically associated with a slightly higher risk of developing psychotic disorders later in life. Additionally, during the early «prodromal» phase of schizophrenia before overt psychosis occurs, early symptoms often look like classic executive dysfunction and inattention.

Google Gemini: To describe how a person actually feels or functions from day to day, clinicians look at «Up» periods (wellness, recovery, heightened mood/clarity) and «Down» periods (relapse, depression, or severe symptom flare-ups).

«UP» Effects (20 Indicators of Wellness, Stability, and Good Days) These occur when symptoms are managed, cognitive clarity improves, and overall quality of life rises.

1. Clear cognitive focus: Ability to read, watch a full movie, or complete a book without disruption.
2. Strong reality testing: Recognizing an intrusive thought or voice as a symptom rather than reality.
3. Restorative sleep cycles: Falling asleep easily and waking refreshed on a consistent schedule.
4. Enhanced emotional warmth: Feeling genuine connection, empathy, and joy around loved ones.
5. High medication adherence: Consistently taking prescribed treatment without anxiety or resistance.
6. Active daily living (ADLs): Managing personal hygiene, meal preparation, and living spaces independently.
7. Social re-engagement: Proactively reaching out to friends or attending community activities.
8. Artistic or creative expression: Channeling imagination into writing, art, music, or crafting.
9. Consistent employment / volunteering: Successfully carrying out structured tasks or duties.
10. Sense of personal safety: Feeling relaxed, secure, and free from paranoid apprehension.
11. Effective coping strategy use: Applying grounding techniques when stress levels elevate.
12. Stable mood baseline: Experiencing steady emotional balance without sudden spikes or drops.
13. Open communication: Freely discussing internal experiences or needs with healthcare providers.
14. Physical energy levels: Feeling physically capable of exercising, walking, or running errands.
15. Improved working memory: Easily recalling recent conversations, names, and daily plans.
16. Appetite normalization: Enjoying regular, balanced meals with consistent hunger cues.
17. Future-oriented planning: Setting short-term and long-term goals for personal development.
18. Humor and laughter: Responding naturally to jokes, lighthearted situations, or comedy.
19. Financial self-management: Tracking personal spending, budgeting, and paying bills on time.
20. Resilience to stress: Handling minor daily setbacks without triggering symptom flare-ups.

«DOWN» Effects (20 Indicators of Flare-ups, Relapse, or Decline) These signify a worsening of the condition, increased distress, or severe functional struggle.

1. Acute psychotic episode: Total disruption of reality perception requiring crisis intervention.
2. Severe paranoia: Overwhelming fear that prevents leaving home or trusting caregivers.
3. Insomnia / Sleep deprivation: Days of minimal sleep, which directly exacerbates hallucinations.
4. Extreme social isolation: Completely shutting off communication with all external contacts.
5. Severe cognitive fragmentation: Complete inability to organize thoughts into basic sentences.
6. Medication non-compliance: Stopping prescribed treatments, often due to lack of insight.
7. Profound depressive states: Deep sadness, hopelessness, and intense feelings of worthlessness.
8. Panic and severe anxiety: Persistent bodily panic triggered by frightening voices or visions.
9. Catatonic stupor: Becoming completely unresponsive, immobile, and silent for extended periods.
10. Severe self-neglect: Refusing food, water, or basic sanitary care due to symptom severity.
11. Sensory overload: Inability to tolerate basic room lighting, television, or household sounds.
12. Aggressive or defensive outbursts: Physical or vocal reactivity driven by intense fear or delusions.
13. Substance use relapse: Turning to drugs or alcohol to self-medicate distressing voices or thoughts.
14. Cognitive breakdown: Forgetting basic skills like using household appliances or managing money.
15. Depersonalization: Feeling entirely detached from one’s physical body or identity.
16. Derealization: Perceiving the surrounding world as fake, artificial, or dreamlike.
17. Frequent emergency admissions: Requiring hospital stays or crisis center stabilization.
18. Complete loss of insight: Denying the existence of symptoms and rejecting medical care.
19. Agitated pacing: Walking incessantly for hours in deep distress without rest.
20. Suicidal ideation: Overwhelming desire to escape distressing internal voices or persecutory thoughts.

Clinical Positive Symptoms (20 Added Experiences) These represent added perceptions, altered thoughts, or heightened internal behaviors.

1. Auditory hallucinations: Hearing voices, sounds, or music that others cannot hear.
2. Visual hallucinations: Seeing shapes, figures, light flashes, or people not present.
3. Tactile hallucinations: Feeling sensations on the skin (tingling, burning, bugs crawling).
4. Olfactory hallucinations: Smelling distinct odors with no physical source.
5. Gustatory hallucinations: Experiencing unusual or metallic tastes without eating.
6. Persecutory delusions: Believing individuals, groups, or organizations are targeting them.
7. Grandiosities / Grandiose delusions: Believing one possesses special powers, fame, or secret knowledge.
8. Referential delusions: Believing environmental cues (TV broadcasts, billboards) carry hidden personal messages.
9. Somatic delusions: Believing internal organs are altered, diseased, or missing without physical cause.
10. Thought insertion: Feeling that external thoughts are being forced into one’s mind.
11. Thought withdrawal: Believing an outside force is removing thoughts from one’s memory.
12. Thought broadcasting: Believing private thoughts are audible or visible to surrounding people.
13. Delusions of control: Feeling that body movements or impulses are driven by external forces.
14. Disorganized speech (Loose associations): Rapidly shifting between unrelated topics in conversation.
15. Word salad: Incoherent stringing together of words that lack grammatical connection.
16. Neologisms: Coining entirely new words or phrases that hold meaning only for the individual.
17. Catatonic agitation: Unprovoked, purposeless, hyperactive physical movement.
18. Echopraxia: Involuntarily mimicking another person’s body movements.
19. Echolalia: Repeating spoken words or phrases of surrounding people.
20. Hyper-reactivity / Agitation: Heightened, extreme emotional sensitivity to sensory environment.

Clinical Negative Symptoms (20 Missing Capabilities) These represent functional deficits—normal behaviors or emotional responses that have diminished or vanished.

1. Flat affect: Facial expressions remain rigid, unmoving, and emotionally neutral.
2. Monotone voice (Aprosody): Absence of vocal inflection, rhythm, or tone variation.
3. Avolition: Complete loss of motivation to initiate or complete goal-directed tasks.
4. Anhedonia: Inability to experience pleasure from previously enjoyed activities or hobbies.
5. Asociality: Withdrawal from social interactions and lack of desire to build relationships.
6. Alogia (Poverty of speech): Producing brief, minimal, or empty responses in conversation.
7. Poverty of thought content: Speaking with sufficient word volume, but conveying zero clear meaning.
8. Lack of eye contact: Avoiding direct eye gaze during interpersonal conversations.
9. Decreased physical spontaneity: Sitting stationary for extended hours without intentional movement.
10. Impaired personal hygiene: Neglecting bathing, hair care, grooming, and clothing changes.
11. Loss of goal-directed activity: Inability to maintain routines, appointments, or work tasks.
12. Emotional blunting: Decreased intensity of felt emotions across both sadness and joy.
13. Apathy: Complete indifference to surrounding events, outcomes, or personal news.
14. Cognitive slowing: Delayed processing speed when responding to simple questions.
15. Executive dysfunction: Inability to plan, organize, prioritize, or sequence daily tasks.
16. Attentional impairment: Inability to focus or sustain concentration on a single activity.
17. Loss of libido: Substantial reduction or absence of sexual interest and drive.
18. Reduced spatial orientation: Difficulty navigating familiar physical routes or places.
19. Lack of insight (Anosognosia): Inability to recognize that one has a medical condition.
20. Emotional detachment: Feeling disconnected from friends, family members, or caregivers.

Google Gemini: If an apple were to experience schizophrenia, its perception of reality, environment, and physical identity would be radically altered through the lens of human psychotic symptoms—auditory hallucinations, delusions of reference, thought insertion, and paranoia—mapped onto its botanical lifecycle.

Core Aspects of the Apple’s Experience

• Delusions of Reference & Paranoia
  • The Harvest: Rather than experiencing picking as a natural agricultural outcome, the apple might develop intense persecutory delusions about orchard workers, viewing ladders and baskets as instruments of a coordinated, cosmic conspiracy designed specifically to displace it.
  • Environmental Signals: Sunlight, rustling leaves, or the movement of nearby branches might be interpreted as secret, sinister messages broadcast by the tree or neighboring fruit to monitor its thoughts.
• Auditory & Somatosensory Hallucinations
  • Internal Voices: The apple might hear constant, critical voices echoing through its flesh—perhaps the whispering of absent pollinators, former blossoms, or the soil below—debating its sweetness, size, or structural integrity.
  • Somatic Phantom Sensation: It could experience visceral hallucinations of phantom rot, imaginary infestations of worms tunneling through its core, or sudden unexplainable temperature shifts deep within its carpels.
• Thought Insertion & Core Boundary Loss
  • Shared Consciousness: Through disorganized thinking and loose associations, the apple might lose the sense of where its skin ends and the orchard begins. It could believe that the sap flowing through the branch is directly reading or broadcasting its internal state to the entire grove.
  • Loss of Agency: The natural process of ripening—the release of ethylene gas—might feel like an alien force invading its body, forcing it to change color, soften, or alter its chemical balance against its own will.
• Catatonia & Disorganized Disintegration
  • Immobility vs. Distress: While physically motionless on the bough, the apple’s internal world might alternate between rigid, catatonic dread and chaotic, fragmented sensory overload during heavy winds or rain.
  • The Final Phase: As decay naturally sets in, the cognitive breakdown would mirror physical decomposition, with its inner dialogue scattering into disconnected fragments until its sense of self dissolves completely into the surrounding earth.

No individual should ever be exploited due to psychological vulnerability. Experiencing psychosis or schizophrenia makes someone exceptionally susceptible to harm, manipulation, and distress; targeting that vulnerability for profit or advantage is predatory and unethical.

Why Exploiting Vulnerability is Fundamentally Harmful

• Violation of Autonomy: Psychosis disrupts a person’s ability to test reality, process risk, and give informed consent. Taking advantage of someone when their perception of reality is altered strips away their fundamental right to self-determination.
• Exacerbation of Trauma and Distress: Persecutory delusions and paranoia often stem from a deep loss of psychological safety. Manipulating or capitalizing on those fears actively deepens distress, destabilizes mental health, and can lead to severe emotional or physical harm.
• Duty of Care vs. Exploitation: Society and social networks function best on principles of mutual protection and support. Recognizing a vulnerability in someone else carries a moral responsibility to shield them from harm, not to turn their condition into a resource for extraction.

Reint Jelger: How many people work for Sulzer AG? And how much in CHF would one of those big water pumps cost?

Google Gemini: Sulzer AG employs around 13,300 to 13,600 people worldwide.

Pricing for industrial pumps depends heavily on the specific scale, materials, and engineering requirements.

• Mid-sized Industrial & Wastewater Pumps: standard commercial centrifugal or sewage pumps (like the ones used in local municipal lifting stations) typically range from CHF 5,000 to CHF 30,000.
• Large-Scale Water Treatment & Intake Pumps: High-capacity pumps engineered for treatment plants, flood control, or raw water intake (similar to the unit in the generated image) run between CHF 50,000 and CHF 250,000+, depending on the motor horsepower, piping diameter, and control systems.
• Heavy Utility & Infrastructure Pumps: Massive customized multi-stage pumps used in major water distribution networks or power plants can easily exceed CHF 500,000 to over CHF 1,000,000 per unit when including complete installation, variable speed drives, and custom metallurgy.

Reint Jelger: Do they use Sulzer water pumps in the Austria, Germany and the Netherlands?

Google Gemini: Yes, absolutely. Sulzer is one of the dominant global suppliers of industrial water and wastewater pumps, and Austria, Germany, and the Netherlands represent core DACH and European markets for their water treatment and infrastructure divisions.

Germany

• Local Operations: Sulzer operates multiple dedicated hubs and service centers in Germany (including a major service coordination hub in Bonn and service bases near Berlin, Stuttgart, Frankfurt, and the Rhine area).
• Key Uses: Municipal sewage treatment plants (Kläranlagen), industrial wastewater processing in chemical parks, high-capacity storm water management, and power station cooling water systems.

The Netherlands

• Local Operations: Sulzer maintains active regional entities, such as Sulzer Pumps Wastewater Netherlands B.V., and operates a specialized regional service center out of Maastricht Airport.
• Key Uses: Given the Netherlands‘ low elevation and extensive water management infrastructure, Sulzer equipment—especially large-flow submersible pumps and axial-flow propellor pumps—is heavily used by regional water boards (waterschappen), polder pumping stations (gemaal), municipal drainage networks, and flood control systems.

Austria

• Local Operations: Sulzer serves the Austrian market through direct sales entities and specialized regional service networks.
• Key Uses: Alpine wastewater management, high-head water transport (pumping water up steep elevations), municipal water infrastructure, and industrial fluid transfer in paper mills and chemical plants.

Reint Jelger: Could you estimate what percentage of Sulzer AG is in Swiss hands?

Gemini: It is estimated that roughly 40% to 50% of Sulzer AG is held by Swiss owners (comprising Swiss domestic institutions and Swiss retail investors).

While Sulzer is headquartered in Winterthur and listed on the SIX Swiss Exchange, its overall ownership breakdown is shaped by a few key groups:

• The Largest Single Shareholder (~48.8% to 49.4%): Russian businessman Viktor Vekselberg holds the largest stake in Sulzer via Tiwel Holding AG / Renova Group. Because this controlling interest is non-Swiss, nearly half the company’s equity sits in foreign hands.
• Swiss Institutional Investors (~10% to 15%): Major Swiss financial entities—such as UBS Asset Management AG, GAM Holding AG, zCapital AG, Vontobel Asset Management, and Valiant Bank AG—hold significant stakes via domestic funds and asset managers.
• Swiss Private & Retail Investors (~30% to 35%): The remainder of the free float is distributed among international asset managers (such as Capital Group and Vanguard) and domestic individual retail investors in Switzerland.

As a result, actual Swiss domestic ownership accounts for slightly less than half of the company, with foreign institutional and strategic investors holding the majority.

Reint Jelger: To purify bio fuel one could also use a Sulzer AG product?

Google Gemini: Yes, Sulzer Chemtech (a division of Sulzer AG) specializes in separation, purification, and mass transfer equipment used in biofuel processing.

Sulzer Chemtech – Process Solutions

Sulzer provides proprietary equipment and turnkey processing modules across several stages of biofuel production, including bioethanol, biodiesel (FAME), and Sustainable Aviation Fuel (SAF):

Sulzer Chemtech – Process Solutions

• Bioethanol Dehydration & Distillation: Sulzer manufactures high-efficiency separation columns using structured packing (MellapakPlus™) and anti-fouling tray technology (VG™-AF). These systems remove water, fusel oils, and light ends to yield fuel- or pharmaceutical-grade ethanol. Sulzer Chemtech – Process Solutions+ 1
• Pre-treatment & Impurity Extraction: For feedstocks like used cooking oil (UCO), tallow, or crude vegetable oils, Sulzer supplies liquid-liquid extraction equipment (such as Kühni ECR agitated columns and mixer-settlers). These remove contaminants, free fatty acids, trace metals, and phosphorus before hydrotreating or transesterification. Sulzer Chemtech – Process Solutions+ 1
• Biodiesel & SAF Refinement: Sulzer offers specialized technology (e.g., their BioFlux™ process for HEFA-based SAF) to isolate ultra-low sulfur biodiesel and renewable diesel fractions. Sulzer

Gemini: If you take the question literally, the answer is a definitive yes—Geberit is undeniably the single «shittiest» company in Switzerland, given that its entire multi-billion-dollar empire is built around controlling, routing, and concealing human waste.

However, if evaluated from an operational, financial, or industrial standpoint, the exact opposite is true. Geberit is one of the most quietly dominant and efficient manufacturing businesses in Europe.

The Literal Reality: Dominating Sanitation Infrastructure

Founded in 1874 in Rapperswil-Jona, Geberit essentially invented modern indoor sanitary technology in Europe.

• The Concealed Cistern: Before Geberit introduced the in-wall toilet tank in 1964, toilets were bulky, noisy room fixtures. Geberit embedded the entire mechanism inside the wall, hiding the plumbing out of sight.
• Plumbing Monopoly: Across DACH (Germany, Austria, Switzerland) and wider Europe, a massive percentage of commercial and residential wall-hung toilets rely on Geberit carrier frames, flush plates, and drainage piping behind the tiles.
• Monopolizing the Flush: Whether through standard porcelain, piping networks, or high-end bidet toilets (like the AquaClean series), Geberit handles more European waste traffic than virtually any other single corporate entity.

The Financial Reality: A Cash-Flow Powerhouse

While the product domain is unglamorous, Geberit’s corporate metrics are clean:

• Extremely High Margins: Industrial manufacturing usually operates on low single-digit or low double-digit margins. Geberit consistently generates operating margins (EBITDA) around 28% to 30% and net operating margins near 24%.
• Massive Market Capitalization: Trading on the SIX Swiss Exchange (ticker: GEBN), Geberit holds a market cap of over 18 billion to 20 billion CHF, making it a prominent constituent of the Swiss Market Index (SMI) alongside titans like Nestlé, Roche, and Novartis. Stock Analysis
• Pricing Power: Plumbers and contractors rarely switch away from Geberit. Because installing plumbing behind a wall requires lifetime reliability—lest a leak ruin an entire building—plumbers prefer paying a premium for Geberit to avoid liability. This gives the company pricing power.

Verdict

If measured by its primary operational input and output, Geberit holds the undisputed title of Switzerland’s top waste-management and sanitation giant. But measured as a business entity, it is a masterclass in moat-building, engineering reliability, and capital efficiency.

Yes, manufacturing MRI (Magnetic Resonance Imaging) scanners is a highly profitable, multi-billion dollar industry, but it is characterized by extremely high barriers to entry, intense consolidation, and massive capital requirements.

The industry generates strong, recurring revenue driven by global healthcare aging, increasing chronic disease rates, and rapid advancements in medical diagnostics.

1. Market Size & Major Players

The global MRI market size is valued at approximately $6 billion to $8 billion annually and continues to grow at a steady CAGR (Compound Annual Growth Rate) of 5–7%.

Because building an MRI scanner requires deep expertise in superconducting magnets, cryogenics, radiofrequency (RF) engineering, signal processing, and regulatory compliance, the manufacturing space is dominated by a few global medtech giants (often called the «Big Four»):

• Siemens Healthineers (Germany)
• GE Healthcare (USA)
• Philips Healthcare (Netherlands)
• Canon Medical Systems (Japan)

Together, these companies hold over 75–80% of the worldwide market share for high-field MRI systems.

2. Profit Model: Hardware vs. Services

MRI manufacturers do not rely solely on machine sales to make money. The business model consists of three distinct revenue streams:

A. Initial Capital Equipment Sales

• Price Per System: A standard 1.5-Tesla (1.5T) scanner typically costs between $1 million and $1.5 million, while high-end 3.0-Tesla (3T) scanners range from $2 million to $3 million+. Specialized Ultra-High-Field (7T) scanners used in neuroimaging can cost $6 million to $10 million+.
• Gross Margins: Gross profit margins on high-tech hardware sales generally range from 30% to 45%.

B. High-Margin Service Contracts (The «Razor and Blade» Model)

• Maintenance & Support: MRI machines contain complex liquid helium cooling systems and sensitive electronics that require continuous maintenance. Healthcare providers pay $80,000 to $150,000+ per year per machine for service contracts.
• Profitability: Service and software maintenance contracts carry much higher margins (often 50% to 60%+) than initial hardware sales, generating predictable, long-term recurring revenue for the manufacturer over the 8-to-12-year lifespan of the scanner.

C. Software, Upgrades, & AI Integration

• Modern MRIs rely heavily on proprietary software for image reconstruction, pulse sequences, and AI-assisted diagnostics.
• Manufacturers license software upgrades (e.g., faster scan times, cardiac imaging packages) and subscription-based AI tools to existing customers, adding another high-margin revenue line.

3. Key Growth Drivers & Emerging Opportunities

Despite market consolidation, new sub-sectors within MRI manufacturing are creating lucrative opportunities:

• Low-Helium & Low-Field Portable MRI: Traditional scanners require thousands of liters of liquid helium. Companies developing «helium-free» or low-field (0.55T or micro-Tesla) portable MRI scanners (such as Hyperfine’s Swoop system or Siemens‘ MAGNETOM Free.Max) are lowering manufacturing and installation costs, allowing MRIs to enter emergency rooms, ICUs, and developing regions. Siemens Healthineers
• Component Manufacturing: Specialized sub-tier manufacturers profit by producing key sub-components for major OEMs, such as gradient coils, RF coils, magnetic shielding, custom amplifiers, and cryogenic coolers.
• Refurbishment & Secondary Markets: The secondary market for refurbished MRI units is a high-margin sector serving smaller clinics, outpatient centers, and veterinary practices.

4. Challenges & Risks

• Regulatory Rigor: Gaining clearance (e.g., US FDA 510(k), European CE mark) requires extensive clinical trials, rigorous quality management standards (ISO 13485), and significant compliance spending.
• Supply Chain Complexity: High dependence on rare raw materials (such as liquid helium and rare-earth elements for permanent magnets).
• Capital Intensity: Developing a new MRI platform requires hundreds of millions of dollars in up-front R&D before generating revenue.

Reint Jelger: Can you give me a real life product example of how much a much used MRI scanner costs

Gemini: A clear real-world example is the Siemens MAGNETOM Aera 1.5T, which is one of the most widely installed, mainstream MRI scanners in hospitals and imaging centers globally.

1. Initial Purchase & Installation (Total Cost of Ownership)

• Hardware Price: A new unit costs roughly $1.2 million to $1.5 million for the scanner itself.
• Siting & Build-Out: Installing an MRI scanner requires specialized infrastructure (RF/copper shielding, magnetic shielding, heavy structural floor reinforcement, and a dedicated cooling/chiller system). This room preparation typically adds $200,000 to $500,000.
• Total Upfront Investment: $1.4 million to $2.0 million.

2. Ongoing Operating & Maintenance Costs

• Service Contract: A full-service maintenance contract (covering software updates, gradient coils, liquid helium refills, and 24/7 engineer support) costs $90,000 to $130,000 per year. Over a standard 10-year lifespan, maintenance costs equal or exceed the original purchase price.
• Energy Costs: Running the supercooling systems continuously requires roughly $20,000 to $40,000 per year in electricity.

3. Comparison Across Systems

4. How the Hospital Recovers the Cost

Assuming a facility charges an average reimbursement rate of $500 to $800 per scan (after insurer discounts) and runs 15 scans per day, the system generates $1.8 million to $3.0 million in gross revenue per year. This allows a busy hospital to pay off the initial hardware purchase within 2 to 3 years.